MUMBAI, India, Sept. 26 -- Intellectual Property India has published a patent application (202527082894 A) filed by Oncoone Research & Development Gmbh, Klosterneuburg, Austria, on Sept. 1, for 'improved bispecific anti-tumor antigen/anti-hsg antibodies for pre-targeting of hyperproliferative disorders.'
Inventor(s) include Schinagl, Alexander; Mirkina, Irina; Puchol Tarazona, Alejandro; and Thiele, Michael Robert.
The application for the patent was published on Sept. 26, under issue no. 39/2025.
According to the abstract released by the Intellectual Property India: "The invention refers to a bispecific anti-tumor antigen/anti-HSG antibody with selected light and heavy chain variable domains which allows improved pre-targeting of tumors for specific delivery of therapeutic or diagnostic agents. Said antibodies have significant affinity for the tumor antigen and sufficient residence time at the desired location. Non-antigen bound antibodies are cleared from the body quickly and exposure of normal tissues is minimized. The humanized anti-HSG antibodies bind with high affinity to both, moieties containing histamine-succinyl-glycyl (HSG) and a tumor antigen, respectively. The bispecific antibody can further be Fc silenced with additional properties such as reduced binding to Fc?R and FcRn to modulated effector functions and half-life. The antibodies can be used for diagnosis and treatment of subjects suffering from malignancies."
The patent application was internationally filed on Feb. 29, 2024, under International application No.PCT/EP2024/055187.
Disclaimer: Curated by HT Syndication.
